Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

Subhashini Jagu, Kihyuck Kwak, Robert L. Garcea, Richard B.S. Roden

Research output: Contribution to journalArticlepeer-review

Abstract

Immunization with L1 as pentavalent capsomeres or virus-like particles (VLPs) generates high and long-lived titers of neutralizing antibodies and protection primarily against the human papillomavirus (HPV) type from which the vaccine was derived. Conversely, vaccination with L2 minor capsid protein derived from multiple HPV types induces lower titer, but more broadly neutralizing and protective antibody responses. We combined the advantages of each protective antigen by immunization with titrated doses of multi-type L2 with either L1 capsomeres or VLP. We observed no significant interference between the L1 and L2 antibody response upon co-administration of L1 vaccines with multi-type L2 vaccines.

Original languageEnglish (US)
Pages (from-to)4478-4486
Number of pages9
JournalVaccine
Volume28
Issue number28
DOIs
StatePublished - Jun 17 2010

Keywords

  • Capsomeres
  • Capsomers
  • Human papillomavirus
  • L1 VLP
  • L2
  • Multimeric

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection'. Together they form a unique fingerprint.

Cite this